Abstract
p53 is a well-known tumor suppressor. However, the regulatory mechanism(s) for p53 expression in B lymphoma cells, and the possible role of p53 in the development of the radioresistance in tumor cells are largely unknown. A human B lymphoma cell line, Karpas1106 (k1106), was used as a model of radioresistance. Apoptosis of k1106 cells was determined using flow cytometry. Expression of p53 was assessed using real time RT-PCR and western blotting. The results showed that irradiation at 8 Gy induced apoptosis in up to 40% of k1106 cells. At the same time, the irradiation markedly increased IL-6 production of the k1106 cells. When k1106 cells were cocultured with regulatory T cells (Tregs) and irradiated, the rate of apoptotic k1106 cells was significantly reduced, indicating an acquired resistance to irradiation. IL-6 derived from the irradiation-treated k1106 cells induced IL-17 expression in Tregs. The IL-17+Foxp3+ T cells suppressed p53 expression in k1106 cells. Collectively, irradiated k1106 cells induce the expression of IL-17 in Tregs, which interferes with the expression of p53 protein in k1106 cells and thereby represses irradiation-triggered apoptosis in k1106 cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Puvvada S, Kendrick S, Rimsza L . Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet 2013; 206: 257–265.
Rivera-Rodriguez N, Cabanillas F . Recent advances in the management of mantle cell lymphoma. Curr Opin Oncol 2013; 25: 716–721.
Domm JA, Thompson M, Kuttesch JF, Acra S, Frangoul H . Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gamma delta T-cell lymphoma: case report and review of the literature. J Pediatr Hematol Oncol 2005; 27: 607–610.
Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T et al. High-dose therapy followed by stem cell transplantation in Hodgkin lymphoma: past and future. Expert Rev Hematol 2013; 6: 451–464.
Nowarski RW . APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood 2012; 120: 366–375.
Sghaier H, Ghedira K, Benkahla A, Barkallah I . Basal DNA repair machinery is subject to positive selection in ionizing-radiation-resistant bacteria. BMC Genomics 2008; 9: 297.
Kim D, Chung K, Chung W, Bae S, Shin D, Hong S et al. Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. Radiat Oncol 2014; 9: 109.
Broustas CG, Lieberman HB . RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels. Prostate 2014; 74: 1359–13570.
Best G, Thompson P, Tam CS . Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 2105–2115.
de Viron E, Michaux L, Put N, Bontemps F, van den Neste E . Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 1445–1451.
Li L, Boussiotis VA . The role of IL-17-producing Foxp3+CD4+ T cells in inflammatory bowel disease and colon cancer. Clin Immunol 2013; 148: 246–253.
Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 2009; 158: 199–204.
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012; 72: 3987–3996.
Radosavljevic G, Ljujic B, Jovanovic I, Srzentic Z, Pavlovic S, Zdravkovic N et al. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 2010; 57: 135–144.
Sun AM, Li CG, Han YQ, Liu QL, Xia Q, Yuan YW . X-ray irradiation promotes apoptosis of hippocampal neurons through up-regulation of Cdk5 and p25. Cancer Cell Int 2013; 13: 47.
Oleinika K, Nibbs RJ, Graham GJ, Fraser AR . Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 2013; 171: 36–45.
Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD et al. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010; 76: 1214–1224.
Kimura A, Kishimoto T . IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830–1835.
Kim SH, Dass CR . p53-targeted cancer pharmacotherapy: move towards small molecule compounds. J Pharm Pharmacol 2011; 63: 603–610.
Solanki AA, LeMieux MH, Chiu BC, Mahmood U, Hasan Y, Koshy M . Long-term outcomes in patients with early stage nodular lymphocyte-predominant hodgkin lymphoma treated with radiotherapy. PLoS ONE 2013; 8: e75336.
Cheng JC, Bai A, Beckham TH, Marrison ST, Yount CL, Young K et al. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest 2013; 123: 4344–4358.
Trikha M, Corringham R, Klein B, Rossi JF . Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653–4665.
Wedlake LJ, Khan K, Ahmedi B, Thomas K, Abraham D, Andreyev N . Letter in response to article: a pilot study examining circulating interleukin-6 and transforming growth factor-beta levels during pelvic radiation therapy. Am J Clin Oncol 2013; 36: 102–103.
Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY . IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004; 111: 653–661.
Chen MF, Hsieh CC, Chen WC, Lai CH . Role of interleukin-6 in the radiation response of liver tumors. Int J Radiat Oncol Biol Phys 2012; 84: e621–e630.
Gougelet A, Mansuy A, Blay JY, Alberti L, Vermot-Desroches C . Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. PLoS ONE 2009; 4: e8026.
Wang BQ, Zhang CM, Gao W, Wang XF, Zhang HL, Yang PC . Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol 2011; 137: 1525–1533.
Hemdan NY . Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol Lett 2013; 149: 123–133.
Qu Y, Zhang B, Liu S, Zhang A, Wu T, Zhao Y . 2-Gy whole-body irradiation significantly alters the balance of CD4+CD25− T effector cells and CD4+CD25+Foxp3+ T regulatory cells in mice. Cell Mol Immunol 2010; 7: 419–427.
Ganesan AP, Johansson M, Ruffell B, Beltran A, Lau J, Jablons DM et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 2013; 191: 2009–2017.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, Q., Xu, X., Zhong, W. et al. IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis. Cell Mol Immunol 12, 366–372 (2015). https://doi.org/10.1038/cmi.2014.122
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2014.122
Keywords
This article is cited by
-
Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
Nature Communications (2024)
-
The IL-17 family in diseases: from bench to bedside
Signal Transduction and Targeted Therapy (2023)
-
Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma
Stem Cell Research & Therapy (2022)
-
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
European Journal of Nuclear Medicine and Molecular Imaging (2021)
-
Comparison of time and dose dependent gene expression and affected pathways in primary human fibroblasts after exposure to ionizing radiation
Molecular Medicine (2020)